rs1800630 — TNF -863C>A

TNF promoter variant that disrupts NF-κB p50-p50 binding, reducing TNF-alpha production by ~31% and influencing susceptibility to autoimmune disease and biologic treatment response

See your personal result for TNF

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TNF-863: The Quieter Inflammation Dial

The TNF gene on chromosome 6 encodes tumor necrosis factor-alpha11 tumor necrosis factor-alpha
a master regulator of inflammation produced by macrophages, T cells, and dendritic cells when the immune system is activated. Most attention in TNF genetics falls on the well-known -308G>A variant (rs1800629), but the promoter contains multiple independent regulatory sites. The -863C>A variant sits 863 base pairs upstream of the TNF transcription start site and controls a distinct transcription factor binding site that is mechanistically separate from -308.

The Mechanism

The -863 position in the TNF promoter contains a binding site for NF-κB22 NF-κB
nuclear factor kappa-light-chain-enhancer of activated B cells, a transcription factor family that drives inflammatory gene expression. This site is unusual because it can bind two types of NF-κB dimers: the activating p65-p50 heterodimer AND the inhibitory p50-p50 homodimer. The p50-p50 homodimer acts as a transcriptional repressor at this site — when it binds, it damps down TNF-alpha production in response to bacterial signals like lipopolysaccharide.

The -863C allele (common) accommodates binding of both dimer types. The rare -863A allele disrupts p50-p50 binding by more than 10-fold33 rare -863A allele disrupts p50-p50 binding by more than 10-fold
demonstrated by electromobility shift assays in Udalova et al. 2000 while leaving p65-p50 binding intact. The practical result: the A allele loses the inhibitory p50-p50 brake, but reporter gene assays in human cells show the A allele actually produces about 31% less transcriptional activity at baseline. The paradox is explained by cellular context44 The paradox is explained by cellular context
see Bayley et al. 1999 — the A allele's behavior differs between hepatic cells (lower output) and activated monocytes (altered LPS-inducible response). Carriers of the A allele have significantly lower serum TNF-alpha concentrations at rest.

The Evidence

The foundational study by Bayley et al. (1999)55 Bayley et al. (1999)
A common functional polymorphism (C→A substitution at position -863) in the promoter region of the TNF-alpha gene associated with reduced circulating levels of TNF-alpha established -863C>A as a functional variant with a measurable effect on both transcription and circulating cytokine levels in healthy individuals.

The mechanistic basis was clarified by Udalova et al. (2000)66 Udalova et al. (2000)
Functional consequences of a polymorphism affecting NF-κB p50-p50 binding to the TNF promoter region, which showed that the -863C allele permits p50-p50 repressor binding while -863A selectively abolishes it — meaning the two alleles change which NF-κB dimers can control the TNF gene in stimulated immune cells.

In a cardiac surgery cohort, Sablotzki et al. (2011)77 Sablotzki et al. (2011)
Tumor necrosis factor-α -863 C/A promoter polymorphism affects the inflammatory response after cardiac surgery demonstrated that CC homozygotes had higher TNF-alpha levels preoperatively and throughout the postoperative course, while AA carriers showed lower inflammatory responses across all time points — providing clinical confirmation of the functional difference.

Autoimmune associations for rs1800630 are mixed by population. A study from India found the -863A allele associated with lupus nephritis phenotype in SLE patients (OR 1.62, 95% CI 1.04–2.53, p = 0.034), and a synergistic interaction with HLA-DRB1*07 was identified (combined OR 4.79, 95% CI 1.73–13.29). In the Iranian Lor population, A allele frequency was significantly elevated in SLE cases vs. controls. Conversely, the -863A allele has been associated with reduced COPD susceptibility and milder disease severity in COPD.

For biologic treatment response in rheumatoid arthritis, the -863 AA genotype was significantly overrepresented in etanercept responders, while the CC genotype was more common among non-responders — a pattern opposite to rs1800629, consistent with the lower baseline TNF production in AA carriers making TNF blockade more effective.

Practical Implications

The -863 variant operates differently from -308. Where the -308A allele drives elevated TNF production and autoimmune risk, the -863A allele reduces baseline TNF-alpha and alters how the immune system responds to bacterial signals. A allele carriers have a lower inflammatory "idle" but may have dysregulated immune responses in specific contexts — particularly relevant for conditions where TNF signaling is centrally involved (SLE, AMD).

For people with RA or other inflammatory diseases requiring anti-TNF biologic therapy, the -863 genotype provides additional predictive information about likely treatment response.

Interactions

rs1800630 is located within the same TNF promoter cluster as rs180062988 rs1800629
TNF -308G>A, the most studied TNF promoter variant, rs179972499 rs1799724
TNF -857C>T, and rs3615251010 rs361525
TNF -238G>A. These promoter variants are in partial linkage disequilibrium. Haplotype analyses suggest that the combination of TNF -863A with -308A may have additive or synergistic effects on autoimmune susceptibility. The -863 locus operates through NF-κB p50-p50 modulation; the -308 locus operates through a distinct mechanism, making the combined effect of carrying risk alleles at both positions biologically plausible for compound action.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard TNF Regulation Normal

Normal TNF-alpha production with standard NF-κB regulatory balance

You have two copies of the common C allele. Your TNF promoter at the -863 position allows full NF-κB p50-p50 homodimer binding, providing normal transcriptional regulation of TNF-alpha. Serum TNF-alpha levels in CC carriers represent the population baseline. About 69% of people carry this genotype. This is the reference state for TNF-alpha regulation at this specific promoter site.

AC Reduced TNF Regulator Intermediate

Partially reduced TNF-alpha production with altered NF-κB p50-p50 dynamics

You carry one A allele and one C allele. Your -863 site partially disrupts p50-p50 NF-κB homodimer binding while maintaining p65-p50 binding. A allele carriers have measurably lower serum TNF-alpha concentrations compared to CC carriers. About 28% of people share this genotype. The functional consequence is an intermediate shift in TNF-alpha regulatory balance that may influence both inflammatory susceptibility and response to anti-TNF therapies.

AA Low TNF Producer Decreased

Substantially reduced baseline TNF-alpha production and altered immune signaling

The AA genotype at -863 creates an unusual immunological profile. The p50-p50 NF-κB homodimer normally acts as a negative regulator at this promoter site — when it binds, it dampens LPS-induced TNF-alpha expression in monocytes. Without p50-p50 binding, AA carriers lose this specific repressor mechanism in the context of bacterial stimulation, even though basal TNF-alpha output is lower. This context- dependent alteration may explain why the A allele is associated with lower serum TNF-alpha at rest but has been linked to inflammatory susceptibility in specific conditions including SLE, AMD, and COPD exacerbation. In cardiac surgery studies, AA carriers showed the lowest postoperative TNF-alpha levels, suggesting better containment of the postoperative inflammatory surge. In RA, the AA genotype significantly increased likelihood of responding to etanercept — patients with lower baseline TNF production appear more responsive to TNF blockade.